Trial Profile
Hematopoietic stem cell transplantation from a related donor with HLA-1 Ag mismatch in the graft-versus-host direction using anti-thymocyte globulin as a GVHD prophylaxis: multicenter phase II trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 31 Dec 2020 Status changed from active, no longer recruiting to completed.
- 27 Apr 2016 Planned End Date changed from 31 Jul 2017 to 31 Jul 2018.
- 28 Aug 2013 New trial record